Literature DB >> 24496282

The current status of minimal residual disease assessment in myeloma.

S K Kumar1, S V Rajkumar1.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24496282     DOI： 10.1038/leu.2013.306

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  19 in total

1.  Novel multi-parameter flow cytometry sensitively detects phenotypically distinct plasma cell subsets in plasma cell proliferative disorders.

Authors:  W G Morice; C A Hanson; S Kumar; L A Frederick; C E Lesnick; P R Greipp
Journal:  Leukemia       Date:  2007-04-26       Impact factor: 11.528

2.  Could CR mean cure?

Authors:  Bart Barlogie; John Crowley
Journal:  Blood       Date:  2011-07-21       Impact factor: 22.113

Review 3.  Cure of multiple myeloma -- more hype, less reality.

Authors:  P Hari; M C Pasquini; D H Vesole
Journal:  Bone Marrow Transplant       Date:  2006-01       Impact factor: 5.483

4.  High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma.

Authors:  Bruno Paiva; Norma C Gutiérrez; Laura Rosiñol; María-Belén Vídriales; María-Ángeles Montalbán; Joaquín Martínez-López; María-Victoria Mateos; María-Teresa Cibeira; Lourdes Cordón; Albert Oriol; María-José Terol; María-Asunción Echeveste; Raquel de Paz; Felipe de Arriba; Luis Palomera; Javier de la Rubia; Joaquín Díaz-Mediavilla; Anna Sureda; Ana Gorosquieta; Adrian Alegre; Alejandro Martin; Miguel T Hernández; Juan-José Lahuerta; Joan Bladé; Jesús F San Miguel
Journal:  Blood       Date:  2011-11-29       Impact factor: 22.113

5.  Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR.

Authors:  M Emig; S Saussele; H Wittor; A Weisser; A Reiter; A Willer; U Berger; R Hehlmann; N C Cross; A Hochhaus
Journal:  Leukemia       Date:  1999-11       Impact factor: 11.528

6.  Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.

Authors:  Michele Cavo; Paola Tacchetti; Francesca Patriarca; Maria Teresa Petrucci; Lucia Pantani; Monica Galli; Francesco Di Raimondo; Claudia Crippa; Elena Zamagni; Antonio Palumbo; Massimo Offidani; Paolo Corradini; Franco Narni; Antonio Spadano; Norbert Pescosta; Giorgio Lambertenghi Deliliers; Antonio Ledda; Claudia Cellini; Tommaso Caravita; Patrizia Tosi; Michele Baccarani
Journal:  Lancet       Date:  2010-12-09       Impact factor: 79.321

7.  Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.

Authors:  Ola Landgren; Robert A Kyle; Ruth M Pfeiffer; Jerry A Katzmann; Neil E Caporaso; Richard B Hayes; Angela Dispenzieri; Shaji Kumar; Raynell J Clark; Dalsu Baris; Robert Hoover; S Vincent Rajkumar
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

8.  F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma.

Authors:  Twyla B Bartel; Jeff Haessler; Tracy L Y Brown; John D Shaughnessy; Frits van Rhee; Elias Anaissie; Terri Alpe; Edgardo Angtuaco; Ronald Walker; Joshua Epstein; John Crowley; Bart Barlogie
Journal:  Blood       Date:  2009-05-14       Impact factor: 22.113

Review 9.  Treatment of myeloma: cure vs control.

Authors:  S Vincent Rajkumar
Journal:  Mayo Clin Proc       Date:  2008-10       Impact factor: 7.616

10.  Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study.

Authors:  Andy C Rawstron; J Anthony Child; Ruth M de Tute; Faith E Davies; Walter M Gregory; Sue E Bell; Alexander J Szubert; Nuria Navarro-Coy; Mark T Drayson; Sylvia Feyler; Fiona M Ross; Gordon Cook; Graham H Jackson; Gareth J Morgan; Roger G Owen
Journal:  J Clin Oncol       Date:  2013-06-03       Impact factor: 44.544
View more
  10 in total

1.  Tumoricidal Effects of Macrophage-Activating Immunotherapy in a Murine Model of Relapsed/Refractory Multiple Myeloma.

Authors:  Jeffrey Lee Jensen; Alexander Rakhmilevich; Erika Heninger; Aimee Teo Broman; Chelsea Hope; Funita Phan; Shigeki Miyamoto; Ioanna Maroulakou; Natalie Callander; Peiman Hematti; Marta Chesi; P Leif Bergsagel; Paul Sondel; Fotis Asimakopoulos
Journal:  Cancer Immunol Res       Date:  2015-05-04       Impact factor: 11.151

Review 2.  New criteria for response assessment: role of minimal residual disease in multiple myeloma.

Authors:  Bruno Paiva; Jacques J M van Dongen; Alberto Orfao
Journal:  Blood       Date:  2015-04-02       Impact factor: 22.113

3.  Multiple myeloma patients in long-term complete response after autologous stem cell transplantation express a particular immune signature with potential prognostic implication.

Authors:  A Arteche-López; A Kreutzman; A Alegre; P Sanz Martín; B Aguado; M González-Pardo; M Espiño; L M Villar; D García Belmonte; R de la Cámara; C Muñoz-Calleja
Journal:  Bone Marrow Transplant       Date:  2017-04-03       Impact factor: 5.483

4.  Single-molecule analysis reveals widespread structural variation in multiple myeloma.

Authors:  Aditya Gupta; Michael Place; Steven Goldstein; Deepayan Sarkar; Shiguo Zhou; Konstantinos Potamousis; Jaehyup Kim; Claire Flanagan; Yang Li; Michael A Newton; Natalie S Callander; Peiman Hematti; Emery H Bresnick; Jian Ma; Fotis Asimakopoulos; David C Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-08       Impact factor: 11.205

5.  cfTrack: A Method of Exome-Wide Mutation Analysis of Cell-free DNA to Simultaneously Monitor the Full Spectrum of Cancer Treatment Outcomes Including MRD, Recurrence, and Evolution.

Authors:  Shuo Li; Weihua Zeng; Xiaohui Ni; Yonggang Zhou; Mary L Stackpole; Zorawar S Noor; Zuyang Yuan; Adam Neal; Sanaz Memarzadeh; Edward B Garon; Steven M Dubinett; Wenyuan Li; Xianghong Jasmine Zhou
Journal:  Clin Cancer Res       Date:  2022-05-02       Impact factor: 13.801

6.  MMSA-1 expression pattern in multiple myeloma and its clinical significance.

Authors:  Shan Meng; Chenyang Lu; Wanggang Zhang; Wenjun Shen; Yongchang Wei; Dan Su; Fuling Zhou
Journal:  Clin Exp Med       Date:  2015-10-22       Impact factor: 3.984

Review 7.  Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives.

Authors:  Alessandra Romano; Giuseppe Alberto Palumbo; Nunziatina Laura Parrinello; Concetta Conticello; Marina Martello; Carolina Terragna
Journal:  Front Oncol       Date:  2019-08-20       Impact factor: 6.244

8.  Exonic variants in multiple myeloma patients associated with relapsed/ refractory and response to bortezomib regimens.

Authors:  Ashraf Kakoo; Mustafa Al-Attar; Taban Rasheed
Journal:  Saudi J Biol Sci       Date:  2021-09-16       Impact factor: 4.219

9.  Gene expression profile alone is inadequate in predicting complete response in multiple myeloma.

Authors:  S B Amin; W-K Yip; S Minvielle; A Broyl; Y Li; B Hanlon; D Swanson; P K Shah; P Moreau; B van der Holt; M van Duin; F Magrangeas; P Pieter Sonneveld; K C Anderson; C Li; H Avet-Loiseau; N C Munshi
Journal:  Leukemia       Date:  2014-04-15       Impact factor: 11.528

10.  Chromothripsis in Treatment Resistance in Multiple Myeloma.

Authors:  Kyoung Joo Lee; Ki Hong Lee; Kyong-Ah Yoon; Ji Yeon Sohn; Eunyoung Lee; Hyewon Lee; Hyeon-Seok Eom; Sun-Young Kong
Journal:  Genomics Inform       Date:  2017-09-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.